MIT Startup Exchange is seeking 8-10 startups to present at its Virtual Workshop on Digital Health on Friday March 26, 11am.
Introduced by Marcus Dahllof, Program Director, MIT Startup Exchange
AI-Powered Tool for Tracking Building Permits, Zoning Cases, and Development Activity John Devine Founder & CEO, Civic Atlas
Civic Atlas is a dynamic platform designed to enhance civic engagement and decision-making through data-driven insights. By integrating geospatial analytics, real-time data visualization, and AI-powered tools, Civic Atlas empowers governments, organizations, and communities to better understand urban development, infrastructure, and social dynamics. The platform enables users to track policy impacts, optimize resource allocation, and foster transparent, evidence-based governance. Whether used for city planning, environmental monitoring, or public services, Civic Atlas bridges the gap between complex data and actionable strategies, driving smarter, more sustainable communities. With its intuitive interface and powerful analytics, Civic Atlas transforms how we navigate civic challenges.
Evonik’s Polymer Processing and Testing Lab in Allentown, PA, formerly used exclusively for internal R&D, is now available to startups through a new pilot program. The lab offers services ranging from collaborative research to defined analytical testing. Companies developing advanced polymer compounds or applications, especially in high-performance materials like polyamide 12 and PEEK, are encouraged to apply.
MIT Startup Exchange presents its September Startup Workshop, centered around real-world IoT and edge computing. Many companies are grappling with how to use IoT and data/AI in their organization to monitor, predict, improve, and transform what they do. Meanwhile, many MIT startups are developing and providing innovative technology solutions to answer these very questions for industry. This workshop will present perspectives from industry leaders, academics, and corporate investors, while also showcasing select MIT startups in the field.
A leading pharmaceutical company in Amyotrophic Lateral Sclerosis (ALS) is interested in speaking with startups whose technology could contribute to very early diagnosis of the disease.
Takeda is looking for new approaches and technologies that can help them address challenges/opportunities in gastroenterology, oncology, neuroscience and rare genetic & hematology.
David Shrier, CEO & founder, Distilled Identity